智通财经APP讯，启明医疗-B(02500)发布截至2024年12月31日止年度业绩，该集团期内取得收益人民币4.71亿元。
公告称，于报告期内，公司持续聚焦结构性心脏病领域，通过优化研发管线布局，进一步提升研发效率，集中资源推进核心重点管线的临床进展。全球临床研发项目取得多项重要里程碑，展现公司强大的全球临床研发及运营实力，国际化进程不断深化。公司自主研发首款自膨干瓣TAVR产品Venus-PowerX、首款球扩干瓣TAVR产品Venus-Vitae和肺动脉瓣膜产品VenusP-Valve相继开展临床试验，临床进展稳步推进中;三尖瓣置换产品Cardiovalve欧洲关键性临床研究患者入组进展顺利，即刻术后效果优异，展现出优秀的安全性和有效性，深受海外专家医生好评。这些产品未来有望为全球患者提供更加优质的治疗方案。
截至本公告日期，公司已成功建立由十款创新器械组成的产品管线，涵盖心脏瓣膜疾病领域。心脏瓣膜类疾病介入治疗是集团布局的核心治疗领域。公司产品包括已商业化四款TAVR产品–VenusA-Valve，VenusA-Plus，VenusA-Pro和VenusA-Deluxe，一款TPVR产品VenusP-Valve，二款经导管手术配件GSheath可扩张导管鞘和TAV0球囊扩张导管;正在进行临床试验的产品包括新一代TAVR产品Venus-PowerX和Venus-Vitae，可同时用于TMVR和TTVR的创新器械Cardiovalve以及TPVR产品VenusP-Valve。
更多港股重磅资讯，下载智通财经app
更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.